Reprometabolic Syndrome Mediates Subfertility in Obesity
生殖代谢综合征介导肥胖导致的生育能力低下
基本信息
- 批准号:9269600
- 负责人:
- 金额:$ 30.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-04 至 2020-02-29
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdverse effectsAnti-Inflammatory AgentsAnti-inflammatoryBarker HypothesisBehavior TherapyBody Weight decreasedCardiovascular DiseasesCharacteristicsChronicClinicalClosure by clampConceptionsDevelopmentDiabetes MellitusDietDietary InterventionDoseEstradiolEuglycemic ClampingExcretory functionFatty AcidsFatty acid glycerol estersFunctional disorderGNRH1 geneGonadal Steroid HormonesGonadotropinsHigh Fat DietHormonalHormonesHyperinsulinismHyperlipidemiaHypogonadotropismInflammationInflammatoryInfusion proceduresInsulinInsulin ResistanceInterventionInvestigationKlinefelter&aposs SyndromeLinkLipidsLipolysisMeasuresMediatingMediationMenstrual cycleMetabolicMethodsModelingMonitorNamesNonesterified Fatty AcidsObesityOmega-3 Fatty AcidsOmega-6 Fatty AcidsOperative Surgical ProceduresOutcomePatternPhenotypePituitary GlandPlayPregnancyPregnancy ComplicationsPreventionProductionProgesteroneRoleSignal TransductionSiteSyndromeTestingWeightWomanWorkcytokinedesignexperimental studyfeedingglucose uptakeinflammatory markerinflammatory milieuinsulin mediatorslipid mediatormenoffspringpublic health relevancereproductivereproductive hormoneresponsesuccesstransmission processurinary
项目摘要
DESCRIPTION (provided by applicant): Obesity plays an adverse role at every stage of conception and pregnancy and mounting evidence implicates relative hypogonadotropic hypogonadism, and reduced menstrual cycle hormone secretion as likely contributors to the subfertility phenotype and possible contributors to complications of pregnancy and the developmental origin of adult diseases such as diabetes and cardiovascular disease. We and others have documented reduced LH, FSH, estradiol and estradiol metabolites and progesterone and progesterone metabolites in obese women compared to those of normal weight. This relative hypogonadotropic hypogonadism partially reverses with surgical weight loss. More recently, we have identified the pituitary gland as a site of defective reproductive axi function in obesity. Our prelminary findings indicate that we can induce deficits in pituitary production of LH and FSH in normal weight women similar to those we have observed in obese women by acutely infusing free fatty acids and insulin (but not either agent alone). The experiments proposed are designed to test the hypothesis that combined excess of free fatty acids and insulin, as typically occurs in obesity, will, at least in part, recapitulate the reprodutive phenotype of obesity in normal weight women (NWW). We have named this phenotype the `reprometabolic syndrome'. Specific Aim 1 predicts that a high- fidelity model of the reprometabolic syndrome can be reliably recreated in normal weight women using a combination of insulin and fatty acid infusion over the short term, and long-term if they are given
a eucaloric, high fat diet (HFD) for one month. Reproductive hormones will be assessed before and after acute lipid and insulin infusion or up to one month of HFD feeding. Aim 2 will quantify how induction of insulin resistance contributes to the reprometabolic syndrome by examining glucose uptake and lipolysis during a two-stage euglycemic insulin clamp administered before and after the HFD intervention and linking the reproductive hormone changes to the specific actions of insulin. Aim 3 will determine key changes in inflammatory markers induced along with the reprometabolic syndrome to identify potential mediators of the insulin and lipid related pituitary suppression seen in simple obesity.
描述(由申请人提供):肥胖在受孕和怀孕的每个阶段都发挥着不利作用,越来越多的证据表明,性腺功能相对低下,月经周期激素分泌减少可能是导致生育力低下表型的原因,也可能是导致妊娠和发育并发症的原因。我们和其他人已经记录了 LH、FSH、雌二醇和雌二醇代谢物以及黄体酮的减少。与正常体重的女性相比,肥胖女性的黄体酮代谢水平随着手术减肥而部分逆转。我们的初步研究结果表明,我们可以通过手术减肥来逆转垂体。与我们通过快速输注游离脂肪酸和胰岛素(但不是单独使用任何一种药物)在肥胖女性中观察到的情况相似,会导致正常体重女性垂体产生 LH 和 FSH 缺陷。所提出的实验旨在检验这样的假设:过量的游离脂肪酸和胰岛素的结合(通常发生在肥胖症中)将至少部分地重现正常体重女性(NWW)的肥胖生殖表型,我们将这种表型命名为。 “再代谢综合征”具体目标 1 预测,在短期内联合使用胰岛素和脂肪酸输注,可以在正常体重女性中可靠地重建高保真再代谢综合征模型,以及如果给予长期的
为期一个月的正常高脂肪饮食 (HFD) 将在急性脂质和胰岛素输注之前和之后进行评估,或者长达一个月的 HFD 喂养将通过以下方式量化胰岛素抵抗的诱导如何导致再代谢综合征。在 HFD 干预之前和之后进行两阶段正常血糖胰岛素钳夹检查期间的葡萄糖摄取和脂肪分解,并将生殖激素的变化与胰岛素的具体作用联系起来,将确定目标 3 的关键变化。炎症标志物与再代谢综合征一起诱导,以识别单纯性肥胖中观察到的胰岛素和脂质相关垂体抑制的潜在介质。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nanette F. Santoro其他文献
Nanette F. Santoro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nanette F. Santoro', 18)}}的其他基金
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial 2/3
子宫内膜异位症女性 IVF 前使用 GnRH 拮抗剂治疗 - 一项前瞻性双盲安慰剂对照试验 2/3
- 批准号:
10696953 - 财政年份:2019
- 资助金额:
$ 30.94万 - 项目类别:
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial 2/3
子宫内膜异位症女性 IVF 前使用 GnRH 拮抗剂治疗 - 一项前瞻性双盲安慰剂对照试验 2/3
- 批准号:
10025599 - 财政年份:2019
- 资助金额:
$ 30.94万 - 项目类别:
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial 2/3
子宫内膜异位症女性 IVF 前使用 GnRH 拮抗剂治疗 - 一项前瞻性双盲安慰剂对照试验 2/3
- 批准号:
10259750 - 财政年份:2019
- 资助金额:
$ 30.94万 - 项目类别:
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial 2/3
子宫内膜异位症女性 IVF 前使用 GnRH 拮抗剂治疗 - 一项前瞻性双盲安慰剂对照试验 2/3
- 批准号:
10478106 - 财政年份:2019
- 资助金额:
$ 30.94万 - 项目类别:
Colorado Women's Reproductive Health Research Career Development Center
科罗拉多州妇女生殖健康研究职业发展中心
- 批准号:
9119083 - 财政年份:2015
- 资助金额:
$ 30.94万 - 项目类别:
Colorado Women's Reproductive Health Research Career Development Center
科罗拉多州妇女生殖健康研究职业发展中心
- 批准号:
8991539 - 财政年份:2015
- 资助金额:
$ 30.94万 - 项目类别:
The Clinical Research/Reproductive Scientist Training Program (CREST)
临床研究/生殖科学家培训计划 (CREST)
- 批准号:
10553877 - 财政年份:2013
- 资助金额:
$ 30.94万 - 项目类别:
The Clinical Research/Reproductive Scientist Training Program (CREST)
临床研究/生殖科学家培训计划 (CREST)
- 批准号:
8474591 - 财政年份:2013
- 资助金额:
$ 30.94万 - 项目类别:
The Clinical Research/Reproductive Scientist Training Program (CREST)
临床研究/生殖科学家培训计划 (CREST)
- 批准号:
10164822 - 财政年份:2013
- 资助金额:
$ 30.94万 - 项目类别:
The Clinical Research/Reproductive Scientist Training Program (CREST)
临床研究/生殖科学家培训计划 (CREST)
- 批准号:
9250796 - 财政年份:2013
- 资助金额:
$ 30.94万 - 项目类别:
相似国自然基金
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
D.formicigenerans菌通过调控FoxP3-Treg影响PD-1抑制剂所致免疫相关不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Soluble epoxide hydrolase and epoxide fatty acid involvement in corneal injury after ammonia exposure: Mechanisms of injury and potential therapeutics using sEH inhibitors and biostable EpFA mimics.
可溶性环氧化物水解酶和环氧化物脂肪酸参与氨暴露后角膜损伤:损伤机制和使用 sEH 抑制剂和生物稳定 EpFA 模拟物的潜在治疗方法。
- 批准号:
10708436 - 财政年份:2023
- 资助金额:
$ 30.94万 - 项目类别:
Targeting T2 inflammation-evoked mechanical endotypes of ASM shortening in asthma
靶向哮喘中 ASM 缩短的 T2 炎症诱发机械内型
- 批准号:
10657988 - 财政年份:2023
- 资助金额:
$ 30.94万 - 项目类别:
Developing multitarget enzyme inhibitors as safe and effective anti-migraine treatments
开发多靶点酶抑制剂作为安全有效的抗偏头痛治疗方法
- 批准号:
10714658 - 财政年份:2023
- 资助金额:
$ 30.94万 - 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
- 批准号:
10621646 - 财政年份:2023
- 资助金额:
$ 30.94万 - 项目类别: